Compare
Cogent Biosciences, Inc. vs Praxis Precision Medicines, Inc. vs BridgeBio Pharma, Inc. vs Janux Therapeutics, Inc.
| Latest fiscal year | Cogent Biosciences, Inc. COGT | Praxis Precision Medicines, Inc. PRAX | BridgeBio Pharma, Inc. BBIO | Janux Therapeutics, Inc. JANX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $502.08M | $10.00M |
| Revenue growth (YoY) | n/a | -100.0% | +126.3% | -5.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -104.2% | n/m |
| Net margin | n/a | n/a | -146.0% | n/m |
| Net income | -$328.94M | -$303.27M | -$732.94M | -$113.62M |
| EPS (Diluted) | -$2.16 | -$13.48 | -$3.78 | -$1.83 |
| Operating cash flow | -$264.44M | -$249.07M | -$445.91M | -$82.23M |
| Free cash flow | -$266.00M | -$249.12M | -$447.01M | -$83.28M |
| Cash & equivalents | $312.01M | $357.33M | $570.12M | $52.33M |
| Total assets | $937.61M | $937.91M | $936.02M | $1.00B |
| Total liabilities | $301.24M | $59.77M | $3.01B | $44.74M |
| Shareholders' equity | $636.37M | $878.14M | -$2.09B | $956.82M |
| Return on year-end equity | -51.7% | -34.5% | n/a | -11.9% |
| Shares outstanding | 160.98M | 25.20M | 194.77M | 60.38M |
Revenue, most recent five fiscal years
| Fiscal year | Cogent Biosciences, Inc. | Praxis Precision Medicines, Inc. | BridgeBio Pharma, Inc. | Janux Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $7.87M Ended 2020-12-31 | $0 Ended 2025-12-31 | $502.08M Ended 2025-12-31 | $10.00M Ended 2025-12-31 |
| 1 year earlier | $22.50M Ended 2019-12-31 | $8.55M Ended 2024-12-31 | $221.90M Ended 2024-12-31 | $10.59M Ended 2024-12-31 |
| 2 years earlier | $9.73M Ended 2018-12-31 | $2.45M Ended 2023-12-31 | $9.30M Ended 2023-12-31 | $8.08M Ended 2023-12-31 |
| 3 years earlier | $8.36M Ended 2017-12-31 | $0 Ended 2022-12-31 | $77.65M Ended 2022-12-31 | $8.61M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $69.72M Ended 2021-12-31 | $3.64M Ended 2021-12-31 |